What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Pathology are his primary areas of study.
Survival rate, Amyloidosis, Transplantation, Primary systemic amyloidosis and Survival analysis are the subjects of his Internal medicine studies.
His Multiple myeloma research includes themes of Monoclonal gammopathy of undetermined significance, Disease and Dexamethasone.
His Surgery research is multidisciplinary, incorporating perspectives in Clinical trial and Intensive care medicine.
His research integrates issues of Progressive disease, Neutropenia, Chemotherapy and Myeloma protein in his study of Gastroenterology.
The various areas that John A. Lust examines in his Pathology study include Chromosomal translocation, Neovascularization and Cytogenetics.
His most cited work include:
- Improved survival in multiple myeloma and the impact of novel therapies (1718 citations)
- Review of 1027 Patients With Newly Diagnosed Multiple Myeloma (1515 citations)
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (768 citations)
What are the main themes of his work throughout his whole career to date?
John A. Lust mostly deals with Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Pathology.
He focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Oncology and, in certain cases, Newly diagnosed and Clinical trial.
His work carried out in the field of Multiple myeloma brings together such families of science as Monoclonal gammopathy of undetermined significance, Bone marrow, Transplantation and Cohort.
His work deals with themes such as Survival rate, Myeloma protein, Progression-free survival and Primary systemic amyloidosis, which intersect with Gastroenterology.
His studies deal with areas such as Fluorescence in situ hybridization, Flow cytometry and Monoclonal as well as Pathology.
His study in Lenalidomide is interdisciplinary in nature, drawing from both Neutropenia and Bortezomib.
He most often published in these fields:
- Internal medicine (64.67%)
- Multiple myeloma (62.08%)
- Surgery (32.14%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (64.67%)
- Multiple myeloma (62.08%)
- Oncology (17.37%)
In recent papers he was focusing on the following fields of study:
John A. Lust focuses on Internal medicine, Multiple myeloma, Oncology, Gastroenterology and AL amyloidosis.
His Internal medicine research focuses on Surgery and how it relates to Clinical trial.
His work on Lenalidomide as part of general Multiple myeloma study is frequently linked to In patient, bridging the gap between disciplines.
His biological study spans a wide range of topics, including Hematopoietic stem cell transplantation and POEMS syndrome.
The concepts of his Gastroenterology study are interwoven with issues in Creatinine, Monoclonal gammopathy of undetermined significance, Odds ratio and Progression-free survival.
His work focuses on many connections between AL amyloidosis and other disciplines, such as Retrospective cohort study, that overlap with his field of interest in Multivariate analysis.
Between 2015 and 2021, his most popular works were:
- Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. (143 citations)
- Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. (67 citations)
- Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. (66 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
John A. Lust spends much of his time researching Internal medicine, Multiple myeloma, Gastroenterology, AL amyloidosis and Surgery.
He has researched Internal medicine in several fields, including Oncology and Pathology.
His Multiple myeloma study combines topics from a wide range of disciplines, such as Clinical trial, Hematology, Hazard ratio, Confidence interval and Stage.
His Gastroenterology research includes elements of Odds ratio, Myeloma protein, Bone marrow and Monoclonal.
His AL amyloidosis research is multidisciplinary, incorporating elements of Survival rate, Proteinuria and Urology.
His Surgery course of study focuses on Bortezomib and Lenalidomide and Macroglobulinemia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
